

Kathryn Lurain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5169471/publications.pdf>

Version: 2024-02-01

19
papers

708
citations

759233

12
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

1005
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. <i>JAMA Oncology</i> , 2019, 5, 1332.	7.1	153
2	Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12805-12810.	7.1	144
3	Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , 2019, 133, 1753-1761.	1.4	87
4	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	12.4	50
5	Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 75-88.	2.2	36
6	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. <i>Blood Advances</i> , 2021, 5, 1660-1670.	5.2	35
7	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. <i>Blood</i> , 2020, 135, 2316-2319.	1.4	33
8	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
9	Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. <i>Blood</i> , 2020, 136, 2229-2232.	1.4	26
10	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. <i>Current HIV/AIDS Reports</i> , 2020, 17, 547-556.	3.1	21
11	Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. <i>Clinical Cancer Research</i> , 2022, 28, 840-850.	7.0	20
12	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 4238-4247.	7.0	17
13	Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. <i>Journal of Clinical Oncology</i> , 2022, 40, 294-306.	1.6	17
14	Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2027110.	5.9	15
15	Emergence of Kaposi's Sarcoma Herpesvirus-Associated Complications Following Corticosteroid Use in TB-IRIS. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy217.	0.9	8
16	Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders. <i>Aids</i> , 2021, 35, 53-62.	2.2	6
17	Dual infection and recombination of Kaposi sarcoma herpesvirus revealed by whole-genome sequence analysis of effusion samples. <i>Virus Evolution</i> , 2020, 6, veaa047.	4.9	5
18	Immunotherapy for KSHV-associated diseases. <i>Current Opinion in Virology</i> , 2022, 55, 101249.	5.4	4

#	ARTICLE	IF	CITATIONS
19	A Mixed Blood-Lymphatic Endothelial Cell Phenotype in Lymphangiomyomatosis and Idiopathic Pulmonary Fibrosis but Not in Kaposi's Sarcoma or Tuberous Sclerosis Complex. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 337-340.	2.9	3